Digestion
Original Paper
Cysteamine-Induced Duodenal Ulcers: A New Model to Test Antiulcer AgentsRobert A. · Nezamis J.E. · Lancaster C. · Badalamenti J.N.Experimental Biology, The Upjohn Company, Kalamazoo, Mich.
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 26, 1974
Accepted: August 13, 1974
Published online: January 23, 2009
Issue release date: 1974
Number of Print Pages: 16
Number of Figures: 0
Number of Tables: 0
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Abstract
Cysteamine, administered as a single subcutaneous or oral dose, produced duodenal ulcers in rats within 24 h. At least 50% of the ulcers perforated at a dose of 425 mg/kg subcutaneously. Cysteamine-induced duodenal ulcers were prevented by an anti-cholinergic agent (methscopolamine bromide), by an antacid, by prostaglandins (PGE2 and 16,16-dimethyl PGE2), by prednisolone, and by interruption of the gastroduodenal transit (pylorus ligation). Fasting did not affect the incidence but reduced the severity (perforations) of the ulcers. The incidence and severity of ulcers was higher in female than in male rats. Desoxycorticosterone and ACTH did not influence the ulcers. Cysteamine inhibited gastric secretion (volume, acid and pepsin output, but not acid and pepsin concentration), in a dose-dependent manner. The pathogenesis of cysteamine-induced duodenal ulcers is unkown. Although cysteamine by itself is antisecretory, it requires some acid secretion and the passage of acid gastric contents over the duodenum to produce ulcers. Duodenal ulcers produced by cysteamine constitute the best model yet devised to test anti-ulcer agents. It is simple, rapid (24 h), and it responds to all antiulcer agents tested so far.
© 1974 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: January 26, 1974
Accepted: August 13, 1974
Published online: January 23, 2009
Issue release date: 1974
Number of Print Pages: 16
Number of Figures: 0
Number of Tables: 0
ISSN: 0012-2823 (Print)
eISSN: 1421-9867 (Online)
For additional information: https://www.karger.com/DIG
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission